The Union Minister of AYUSH and Ports, Shipping & Waterways Shri Sarbananda Sonowal said that the northeastern region possess the greatest potential for the next phase of economic growth of the country. The diversity of flora in the region along with the rich heritage of traditional medicine will act as a catalyst for the development of AYUSH based industries in the region. The Union government is committed to elevate the economic proposition of the Northeast and provide the launch pad for India’s next economic growth.
The Minister was attending the review meeting of the North Eastern Institute of Ayurveda & Homeopathy held at Umiam in the Ri Bhoi district, Meghalaya. While speaking to the media person, the minister stressed about the need for best quality education for students of the region. The best education in Ayurveda nursing and pharmacy as well as professional short-term courses in Panchkarma Therapy so that students from Northeast and from other parts of the country can avail it. The minister stressed on training world class manpower who will be able to drive the economic growth.
The Union Minister said that the government remains committed to make northeast the growth engine of India. In this regard, he highlighted the rich & dynamic flora that nature has bestowed on us. There is a major opportunity for AYUSH based industries to look at northeast as the next destination for their new units. The world class professionals trained at NEIAH and other important training centers under Ministry of AYUSH will complement with the availability of the flora in the region to accelerate growth in the region.
The Union Minister stated that the Govt is committed to develop modern infra in NEIAH. He announced that the Govt will take steps to start PG courses at the institute and stipend for Homoeopathy interns will be increased at par with Ayurveda.
During the review meeting with the top officials of his ministry, the union minister took stock of the steps taken by the government to build capacity in the AYUSH led initiatives. He advised a few course corrections so that results from these initiatives can reach to the end users and people sooner than later.
Read More► Ministry of AYUSH Launches Online Portal to Ease The Process of Licensing Ayurveda Medicine
Hyderabad, Sep 5 (IANS) To give impetus to biopharmaceutical research and manufacturing, the Telangana government on Sunday announced that it is developing Biopharma Hub (B-hub), which will be first of its kind growth phase centre and biopharma scale-up manufacturing facility in India.Industry and Information Technology Minister K. T. Rama Rao tweeted that B-Hub will be operational in 15 months and will help consolidate Telangana's leadership position in biopharma."With built-up area of 100,000 square feet in 2 phases, B-Hub will compliment the extraordinary ecosystem at Genome Valley in Hyderabad," he said, in a series of tweets.The facility is being developed by the Telangana State Industrial Infrastructure Corporation Ltd and Telangana Life Sciences, in an unique partnership model with the Centre's Department of Biotechnology, Cytiva, and Cerestra Ventures."The project is envisioned to be an accelerator for biopharma innovation featuring next gen lab suites, encouraging both Startups & midsized companies to interact and collaborate through collective spaces and lead innovation," said Rama Rao.According to an official note released from the minister's office, annual sales of biopharmaceuticals are now over $200 billion globally, and industry revenue continues to grow at 15 per cent annually. An increasing number and percentage of pharmaceuticals entering the market are biopharmaceuticals, with about 40 per cent of Big Pharma and overall pharmaceutical R&D/pipelines now involving biopharmaceuticals, not drugs (chemical substances).A biopharma scale-up manufacturing facility with a turnkey laboratory space is a key requirement to facilitate the growth of biosimilars in the lifesciences industry. Biopharmaceutical companies are aspiring to advance a molecule from the laboratory to the clinic as quickly as possible without sacrificing product quality, process efficiency, or patient safety. To achieve this goal, companies must navigate the complexities associated with business planning, cell line development, process development, technology, and regulatory and risk assessment, it said.There is no such full-fledged infrastructure anywhere in the country on date and establishment of an end-to-end biopharma upscale facility including bioreactors and vessels which contain cell culture media to the filtration units and the downstream chromatography processes will provide a platform for the start-ups, mid-sized and even large biopharma companies to carry out their pre-clinical validation in the proposed facility, before making significant capex investment in the product. "There is a significant demand of such facility that will reduce the time to market for our companies and single-use set-up ensures adherence to world class regulatory norms," it added.Hyderabad has emerged as leader in pharmaceutical and biotechnology and is well positioned to host such a facility. It is a major scientific and R&D hub with presence of globally renowned institutions such as the Indian Institute of Chemical Technology (IICT), the Centre for Cellular and Molecular Biology (CCMB), the Centre for DNA Fingerprinting and Diagnostics (CDFD), among many others and over 800 life sciences companies.Over the last four decades, Telangana has seen exponential growth in pharmaceuticals accounting for 1/3rd of the country's pharmaceutical production and 30 per cent of all ANDA approvals received by the Indian companies from US FDA. Hyderabad is recognised as the vaccine hub of India and the world, producing about 33 per cent of global vaccines dosages and significantly contributing to elimination of global pain and disease.--IANSms/vd
New York, Aug 20 (IANS) Several drugs that are already in use for other purposes, including one dietary supplement, have shown to block or reduce infection by SARS-CoV2, the virus causing Covid-19, in cells, researchers have found.The study, published in the Proceedings of the National Academy of Science, uses artificial intelligence-powered image analysis of human cell lines during infection with the novel coronavirus.The cells were treated with more than 1,400 individual US Food and Drug Administration-approved drugs and compounds, either before or after viral infection, and screened, resulting in 17 potential hits.Ten of those hits were newly recognised, with seven identified in previous drug repurposing studies, including remdesivir, which is one of the few FDA-approved therapies for Covid-19 in hospitalised patients."Traditionally, the drug development process takes a decade -- and we just don't have a decade," said Jonathan Sexton, Assistant Professor of Internal Medicine at the University of Michigan Medical School."The therapies we discovered are well positioned for phase 2 clinical trials because their safety has already been established," he added.The team validated the 17 candidate compounds in several types of cells, including stem-cell derived human lung cells in an effort to mimic SARS-CoV2 infection of the respiratory tract.Nine showed antiviral activity at reasonable doses, including lactoferrin, a protein found in human breast milk that is also available over the counter as a dietary supplement derived from cow's milk."We found lactoferrin had remarkable efficacy for preventing infection, working better than anything else we observed," Sexton said. He added that early data suggest this efficacy extends even to newer variants of SARS-CoV2, including the highly transmissible Delta variant.The team aims to soon launch clinical trials of the compound to examine its ability to reduce viral loads and inflammation in patients with SARS-CoV2 infection.The study also identified a class of compounds called MEK-inhibitors, typically prescribed to treat cancer, that appear to worsen SARS-CoV2 infection. The finding sheds light on how the virus spreads among cells."People going in for chemotherapy are at risk already due to a lowered immune response. We need to investigate whether some of these drugs worsen disease progression," said Sexton.--IANSrvt/ksk/
Hyderabad, May 26 (IANS) Telangana's Industry and Information Technology Minister K.T. Rama Rao on Wednesday rued that while Hyderabad is the vaccine hub of the world, it has no vaccines to inoculate people against Covid-19."While Hyderabad is the vaccine hub of the world, vaccine manufacturer for the world, it is unfortunate that we don't have vaccines for our own people," he said while inaugurating a Covid care centre in Cyberabad, the information technology district."If we are given enough vaccines, our government has capability to administer one million doses per day. We can cover the entire state in 45 days. It's unfortunate that demand supply equation is quite bad in the country. The demand is quite high while supply is meagre and everything is governed by the Centre," said Rama Rao, who is son of Chief Minister K. Chandrasekhar Rao.KTR, as Rama Rao is popularly known, hoped that the situation will improve. He said it was individual opinion that the Centre should reach out to Pfizer, Moderna, Sinovac and other vaccine manufacturers in the world who can give India the required number of vaccines in shortest possible time."I am also told that there are vaccines which are lying idle elsewhere in the world, in Canada, Denmark and the US. There are vaccines which are pending approval and there are vaccines already approved and which are lying idle elsewhere without consumption and without demand," he said.He wanted the Centre to step up its efforts allow more vaccine manufacturers to enter the country so that demand supply gap is coveredPointing out that Punjab and several state governments have been told by vaccine manufacturers that they don't want to deal directly with the states, he hoped that the Centre will take states into confidence and understand their requirements. He said each state can't have its vaccine strategy. "After all, it is one country and we have to work in sync," he said.The minister said the potential super spreaders and vulnerable sections among people have to be identified and vaccinated. He said the states and the Centre will have to prepare themselves and work together to tackle the next way and that they can't work in isolation.Stating that vaccination is the solution, KTR said the state government was in touch with the Centre to get more doses.The minister, who heads the state Task Force for procurement of vaccines, said the state government has also called tenders for one crore vaccines.--IANSms/vd
Guwahati, May 18 (IANS) While Assam is supplying oxygen to Arunachal Pradesh, Manipur, Mizoram, Tripura and Nagaland, Chief Minister Himanta Biswa Sarma said on Tuesday that his state would also provide 16 metric tonnes of the gas daily to Meghalaya.Talking to his Meghalaya counterpart Conrad K. Sangma over video conference, Sarma said that Assam would continue to supply Meghalaya 16 metric tonne of medical oxygen per day from Amingaon and Bongaigaon as long as the situation demands.An official statement quoting Sarma said that Assam, as the medical oxygen hub, shall serve the whole of northeastern region with optimum utilisation of its oxygen storage and transportation facilities. He said that Assam would collect liquid oxygen from production units outside the region and store it in facilities in the state, from where all other northeastern states can take oxygen as per their need. Sarma also requested Sagma to ensure smooth transportation of goods and passenger vehicles from Brahmaputra valley of Assam to southern Assam's Barak valley through Meghalaya and he assured that transportation of essential items would be seamless and uninterrupted.--IANSsc/vd
Chennai, March 23 (IANS) Online food delivery player Swiggy on Tuesday announced the launch of Health Hub here where customers can order healthy food.According to Swiggy, customers can order healthy food options on Swiggy app.With people looking out for healthy food options, Swiggy worked with nutritionists and restaurants here to come out with over 9,000 dishes from 700 outlets.For instance, millet based dosa/idli like Kambu Dosa, Kuthraivalli Dosa, Millet Idli, Millet Karuvepilai Idli, Wheat Dosa, are all available on Swiggy's Health Hub.Consumers can choose from high-protein, low-carb, vegan, and keto meals across soups, salads, wraps and desserts.While Health Hub provides healthy alternatives to South Indian cuisines in Chennai, it also offers healthy alternatives across all popular cuisines such as Continental, Pan Asian, North Indian, along with a wide selection of juices and desserts, Swiggy said.We want to dispel the common notion that healthy food is hard to find, lacking in taste and expensive, said Vivek Sunder, COO, Swiggy.--IANSvj/in